A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events–Reduction of Cholesterol to Key European Targets Trial.

Aug 17, 2015

Overview : The debate over the cholesterol hypothesis and statins has raged for decades. The early period following the onset of acute coronary syndrome represents a critical stage of coronary heart disease, with a high risk of recurrent events and deaths. The... more

A LONG-AWAITED LDL LOWERING STUDY USING COMBINATION THERAPY IS PRESENTED BY RESEARCHERS

Dec 03, 2014

Overview : STUDY DESIGN A total of 18,144 patients were randomized in 1:1 blinded fashion either to ezetimibe / simvastatin (n=9,067) or to simvastatin alone (n=9,077). The inclusion criteria were (a) hospitalization for ST-elevation myocardial infarction (MI), non ST-elevation myocardial infarction or... more

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomization study

Jun 18, 2012

Overview : The present study sought to assess whether there is a causal relationship between raising HDL and the risk for myocardial infarction (MI). Using a mendelian randomization, the authors found that in patients with genetically higher HDL the risk of MI... more

Changes in HDL cholesterol and cardiovascular outcomes after lipid modification therapy

Jun 18, 2012

Overview : In the present study the authors aimed to replicate the earlier observation from the Framingham Offspring Study that changes in HDL-C associated with lipid modification therapy are associated with a lower risk of cardiovascular events independent of changes in LDL-C... more

Lowering LDL-C with statins in patients at low risk of vascular disease: a meta-analysis

Jun 18, 2012

Overview :   Background Both clinical trials and very large meta-analyses have shown that statins reduce LDL- cholesterol (LDL-C) and prevent cardiovascular disease (CVD) events. This meta-analysis explored the lipid-lowering effects of statin therapy in patients at very low risk of CVD.... more

The effect of the REGN727 anti-PCSK9 monoclonal antibody on LDL cholesterol

May 02, 2012

Overview : Background Proprotein convertase subtilisin kexin type 9 (PCSK9) is a circulating protein that binds to Low Density Lipoprotein LDL Receptors (LDLR), leading to their accelerated degradation, impairing LDL clearance and increasing LDL cholesterol levels. PCSK9 is mainly of hepatic origin,... more